Skip to main content

Table 3 Comparison of clinical symptom improvement rate between Ludangshen and placebo group

From: Ludangshen oral liquid for treatment of convalescent COVID-19 patients: a randomized, double-blind, placebo-controlled multicenter trial

Variables FAS analysis PPS analysis
Ludangshen Placebo P value Ludangshen Placebo P value
Fatigue (n) 94 90   92 89  
 Week 1 52 (55.3) 29 (32.2) 0.002 50 (54.3) 29 (32.6) 0.003
 Week 2 81 (86.2) 38 (42.2)  < 0.001 78 (84.8) 37 (41.6)  < 0.001
Anorexia (n) 68 70   67 68  
 Week 1 49 (72.1) 25 (35.7)  < 0.001 48 (71.6) 25 (36.8)  < 0.001
 Week 2 61 (89.7) 38 (54.3)  < 0.001 60 (89.6) 36 (52.9)  < 0.001
Distension (n) 43 34   42 33  
 Week 1 28 (65.1) 14 (41.2) 0.036 27 (64.3) 14 (42.4) 0.059
 Week 2 38 (88.4) 22 (64.7) 0.013 38 (90.5) 21 (63.6) 0.01
Loose stools (n) 48 52   48 50  
 Week 1 32 (66.7) 24 (46.2) 0.039 32 (66.7) 24 (48.0) 0.062
 Week 2 41 (85.4) 32 (61.5) 0.007 41 (85.4) 30 (60.0) 0.005
Shortness of breath (n) 50 50   49 49  
 Week 1 27 (54.0) 21 (42.0) 0.23 26 (53.1) 21 (42.9) 0.312
 Week 2 44 (88.0) 28 (56.0)  < 0.001 43 (87.8) 28 (57.1) 0.001
  1. FAS full analysis set, PPS per protocol set